Anzeige
Mehr »
Login
Donnerstag, 02.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
"Special Situation"-Aktie mit Multi-Tenbagger-Potenzial im heißesten Rohstoff-Markt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
25 Leser
Artikel bewerten:
(0)

Upcoming Webinar to Inform Public About Access to Investigational Drugs / First in the 'FDA Basics' Series of Online Sessions for the Public

SILVER SPRING, Md., Feb. 19 /PRNewswire-USNewswire/ -- Do you have questions about the use of investigational drugs for treatment purposes? Here is your opportunity to ask experts from the Food and Drug Administration (FDA) about this important topic, or to just listen in to learn more about investigational drugs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) When: Tuesday, Feb. 23, 2010, at 3 p.m. ET Where: https://webmeeting.nih.gov/expandedaccess/

Host: FDA's Office of Special Health Issues (OSHI), 301-827-4460, OSHI@oc.fda.gov

Speakers: Richard Klein, HIV/AIDS program director, OSHI Theresa Toigo, R.Ph., M.B.A., director, OSHI

Also known as experimental drugs, investigational drugs are new drugs that are in the process of being tested for safety and effectiveness. They either have not yet been approved by FDA, or are approved drugs that have not yet been approved for a new use.

Investigational drugs may sometimes be used outside of clinical trials to treat a patient with a serious or immediately life-threatening disease or condition who has no other comparable or satisfactory treatment options. This use is called expanded access, or "compassionate use."

During this webinar, FDA experts will present information on -- factors to consider in deciding whether to seek access to an investigational drug -- ways to access investigational drugs -- how the agency protects patients using investigational drugs

The presentation will run 30 minutes and will include an opportunity to ask questions.

To join the webinar: 1. Click https://webmeeting.nih.gov/expandedaccess/ (or cut and paste it into your Internet browser). 2. Click "Enter as a Guest," fill in your name, then click "Enter Room." 3. Once you enter the meeting room, a popup will appear inviting you to join the teleconference. Type your own telephone number, then click "Call my phone" or "Call me." Answer your phone when it rings and follow the voice prompts to join the teleconference.

NOTE: If your phone number includes an extension, or if you will attend the teleconference only (not the online visual portion), please use the manual dial-in number: 1-866-628-8620 and passcode: 340910

To verify your ability to access the webinar (recommended for first-time Connect users):

1. Click http://nihbreeze.cit.nih.gov/common/help/en/support/meeting_test.htm (or cut and paste it into your Internet browser). 2. If any failures are indicated, click "Send Results" to submit your test results to Tech Support. Then e-mail webmeeting@mail.nih.gov and indicate that you would like assistance with troubleshooting your computer.

This webinar is the first in a series of monthly online sessions hosted by different FDA centers and offices. The webinar series is part of FDA Basics, a Web-based resource aimed at helping the public better understand what the agency does.

Sign up for e-mail notices of new FDA Consumer Updates at: https://service.govdelivery.com/service/subscribe.html?code=USFDA_9.

View the FDA Consumer Update RSS feed at: http://www.fda.gov/AboutFDA/ContactFDA/StayInformed/RSSFeeds/Consumers/rss.xml

FDA Consumer Updates may be posted and published elsewhere without permission. Please credit "FDA Consumer Health Information (www.fda.gov/consumer)" as the source. FDA values feedback on its consumer health information. Send questions, comments, or story ideas to: consumerinfo@fda.hhs.gov.

Photo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO
PRN Photo Desk, photodesk@prnewswire.com

U.S. Food and Drug Administration

CONTACT: FDA's Office of Special Health Issues (OSHI), OSHI@oc.fda.gov

Web Site: http://www.fda.gov/AboutFDA/Basics

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2010 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.